UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

ReShape Lifesciences Inc.

(Name of Issuer)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

761123405

 (CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.          761123405        

CUSIP No.          761123405        

CUSIP No.          761123405        

This Amendment No. 1 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on July 20, 2018 (the “Schedule 13G”).

Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

(a) and (b):

As of the close of business on December 31, 2018, each of the Reporting Persons may have been deemed to have beneficial ownership of 4,765 shares of Common Stock in the aggregate issuable upon exercise of four warrants held by Intracoastal (collectively, the “Intracoastal Warrants”), and all such shares of Common Stock represented beneficial ownership of approximately 0.1% of the Common Stock, based on (1) 3,159,993 shares of Common Stock outstanding as of November 25, 2018 as reported by the Issuer, plus (2) 670,000 shares of Common Stock in the aggregate issued at the closing of the transaction described by the Issuer in its Rule 424B5 prospectus filed with the SEC on December 28, 2018 and (3) 4,765 shares of Common Stock in the aggregate issuable upon exercise of the Intracoastal Warrants.

(c) Number of shares as to which each Reporting Person has:

(i) Sole power to vote or to direct the vote: __ 0 __.

(ii) Shared power to vote or to direct the vote: __ 4,765__ .

(iii) Sole power to dispose or to direct the disposition of __0__ .

(iv) Shared power to dispose or to direct the disposition of __4,765__ .

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ. 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 8, 2019